These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 29946800

  • 1. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.
    Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, Tanda ML, Chiovato L, Wiersinga WM, Bartalena L.
    J Endocrinol Invest; 2018 Dec; 41(12):1425-1432. PubMed ID: 29946800
    [Abstract] [Full Text] [Related]

  • 2. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 3. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves' Disease.
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [Abstract] [Full Text] [Related]

  • 4. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P, Berman DC, Andersen S, Bülow Pedersen I.
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [Abstract] [Full Text] [Related]

  • 5. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, Park DJ, Yi KH, Park YJ, Cho BY.
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
    Shi H, Sheng R, Hu Y, Liu X, Jiang L, Wang Z, Cui D.
    Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease.
    Fukao A, Takamatsu J, Murakami Y, Sakane S, Miyauchi A, Kuma K, Hayashi S, Hanafusa T.
    Clin Endocrinol (Oxf); 2003 May; 58(5):550-5. PubMed ID: 12699435
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients.
    Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, Bernasconi L, Mundwiler E, Mueller B, Christ-Crain M, Meienberg F, Ebrahimi F, Henzen C, Fischli S, Kraenzlin M, Meier C, Schuetz P.
    Eur J Endocrinol; 2017 Apr; 176(4):413-419. PubMed ID: 28100628
    [Abstract] [Full Text] [Related]

  • 15. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H.
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [Abstract] [Full Text] [Related]

  • 16. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
    García-Mayor RV, Álvarez-Vázquez P, Fluiters E, Valverde D, Andrade A.
    Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
    [Abstract] [Full Text] [Related]

  • 17. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
    Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, de Laval D, Abraham-Nordling M, Calissendorff J, Lantz M, Hallengren B, Filipsson Nyström H, Wallin G.
    Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
    [Abstract] [Full Text] [Related]

  • 18. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW, Liu RT, Tung SC, Chien WY, Lu YC, Chen CH, Kuo MC, Hsieh JR, Wang ST.
    J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
    [Abstract] [Full Text] [Related]

  • 19. The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study.
    Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, Gaiti M, Spreafico E, Gallo D, Premoli P, Piantanida E, Tanda ML, Ferrario M, Vitti P, Chiovato L.
    J Endocrinol Invest; 2016 Dec; 39(12):1445-1451. PubMed ID: 27465670
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.